The Senate today approved landmark legislation overhauling the development of medical treatments and cures for patients, which represents the culmination of a multi-year, bipartisan initiative in Congress. Here is a statement from Alliance President and CEO Sue Peschin.
The Aging in Motion (AIM) Coalition hosted its second annual meeting with U.S. Food and Drug Administration (FDA) leaders and leading scientists, industry representatives, and advocates to discuss developments and advances in clinical research and treatment of sarcopenia in Bethesda, Md.
On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.
Today, senior representatives from the U.S. Food and Drug Administration (FDA) and the National Institute on Aging at the National Institutes of Health (NIH) joined with advocates, federal colleagues, researchers, and industry to explore collaborations for advancing the most up-to-date knowledge in Alzheimer’s disease research.
In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.